Company intelligence / Profile preview

Pluri-Elles

Haifa, Haifa District, Israelpluri-elles.mb.ca ↗

Ownership: Private
Employees: ~180
Development stage: Other

Overview

PLX-R18 has been selected by Ukraine’s government for stockpiling as a countermeasure against radiation emergencies; clinical programs include late-stage trials in muscle injury and mid-stage trials in acute radiation syndrome. The platform also supports collaborations with pharma partners on biologic APIs and regenerative medicine applications.

Therapeutic areas: OtherRheumatologyOncologyHematology
Modalities: Cell therapyMesenchymal stem cell therapyStem cell therapy
Industry: Biotech

Partnerships

Key partnership with Hemafund for Ukraine’s national stockpile of PLX-R18 against radiation emergencies ($100M+ value potential over three years)Collaboration with major European pharmaceutical partner to develop animal-free biologic APIs using their platform technology.

Beyond the preview

Go deeper on Pluri-Elles.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri-Elles.

Explore the full profile